News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Data Presented at Connective Tissue Oncology Society (CTOS) 7th Annual Meeting in Prague, Czech Republic


11/15/2012 10:21:57 AM

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced the presentation today of favorable results from a Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma at the Connective Tissue Oncology Society (CTOS) 17th Annual Meeting in Prague, Czech Republic. The poster-discussion presentation was delivered by Dr. Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES